On Tuesday, Altria Group reported second-quarter adjusted earnings that was almost in line with analysts' expectations. However, the cigarette maker warned that cigarette sales declines are worsening, and also expressed current uncertainty on Juul’s international expansion.
Excluding special items such as litigation, costs associated with Altria's investment in Anheuser-Busch InBev and its stake in Canadian cannabis producer Cronos, Altria’s earnings came in at $1.10 a share for the quarter, almost matching the consensus estimate of analysts polled by FactSet.
The company's total sales climbed +5.5% year-over-year to $5.19 billion in the quarter, surpassing analysts’ expectations of $5.09 billion.
Altria also affirmed its projection of full-year adjusted earnings of between $4.15 and $4.27 a share.
However, the company indicated that U.S. cigarette volumes would decline between -5% and -6% this year, as cigarette smokers switch to e-cigarettes. Its prior forecast of the decline was -3.5% to -5%.
Altria also revised its expectations of total domestic cigarette industry volumes decline to -4% to -6% through 2023, compared to the previously forecast range of -4% to -5%. The company feels that part of this can be attributed to 18 states raising the permissible smoking age to 21.
Apparently in a bid to capitalize on the growing e-cigarette market, Altria invested $12.8 billion last year for a 35% stake in e-cigarrette startup Juul. Altria is hoping for Juul’s international growth to boost business, but Altria CEO Howard Willard said it’s “too soon” to judge the outcome. Meanwhile, e-smoking apparently continues to face scrutiny in various parts of the world for its burgeoning popularity among teenagers.
Other recent instances of product-portfolio diversification of the Marlboro-maker include its $1.8 billion investment for a 45% stake in Canadian cannabis company Cronos earlier this year , and its $372 million spending for oral nicotine pouch brand On.
Altria will also begin selling heated tobacco product iQOS, in the U.S. this summer. Philip Morris International will license the device to Altria. The Food and Drug Administration earlier this year gave its approval on iQOS sales in the U.S.
The Stochastic Oscillator for MO moved into oversold territory on June 30, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
MO moved above its 50-day moving average on June 11, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MO advanced for three days, in of 373 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 309 cases where MO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for MO moved out of overbought territory on June 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MO as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MO turned negative on June 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MO broke above its upper Bollinger Band on June 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MO's P/B Ratio (0.000) is slightly lower than the industry average of (3.589). P/E Ratio (9.837) is within average values for comparable stocks, (20.144). MO's Projected Growth (PEG Ratio) (4.018) is very high in comparison to the industry average of (0.992). Dividend Yield (0.070) settles around the average of (0.055) among similar stocks. MO's P/S Ratio (4.926) is slightly higher than the industry average of (2.122).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 69, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a holding company which produces and markets tobacco products
Industry Tobacco